<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3258">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02017301</url>
  </required_header>
  <id_info>
    <org_study_id>GAS-800-12-13-1</org_study_id>
    <nct_id>NCT02017301</nct_id>
  </id_info>
  <brief_title>Vector Analysis of Body Composition in Cirrhotic Patients With Infections</brief_title>
  <official_title>Impact of Acute Infections in Cirrhotic Patients on Body Composition Determined by Bioelectrical Impedance and Vector Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <authority>Mexico: Secretaria de Salud</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inadequate nutritional support and infection status in the cirrhotic patient directly affect
      body composition.

      Cirrhotic patients with infection secondary to their disease, often have protein-energy
      malnutrition and significant loss of muscle mass after the time of infection.

      Good nutritional status improves quality of life and may reduce the number of complications
      or more infections. Dietary treatment in cirrhotic patients presenting with any cause
      infection could consider a strategy to prevent and control some of its complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhotic patients with infection secondary to their disease, often have protein-energy
      malnutrition and significant loss of muscle mass after the time of infection.

      Patients who maintain good nutrition are more likely to tolerate the side effects of time
      and treatment against infection.

      Good nutritional status improves quality of life and may reduce the number of complications
      or more infections. Dietary treatment in cirrhotic patients presenting with any cause
      infection could consider a strategy to prevent and control some of its complications.

      Analyze changes in body composition and muscle mass during the infection process.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Body composition</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anthropometric measurements will be taken: weight, height, triceps skinfold thickness, and bioelectrial impedance vector analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood sampling</measure>
    <time_frame>1-2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples will be taken: ammonia, interleukins (IL-1, IL-6 , IL-10 TNFa)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Cirrhotic patients with infection</arm_group_label>
    <description>Blood samples Bioelectrial impedance vector analysis Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Population will be selected from the Liver Clinic at the Department of Gastroenterology at
        at tertiary care center in Mexico
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18, 75 years old

          -  Patient diagnosed with liver cirrhosis. The diagnosis of cirrhosis can be done by any
             of the following definitions:

          -  Liver biopsy showing cirrhosis

          -  Operational definition: They are met two or more of the following criteria:

          -  Albumin &lt;3.5

          -  International Normalized Ratio (INR) &gt;1.3

          -  Total bilirubin &gt;2

          -  Image (USG) compatible with cirrhosis and portal hypertension

          -  Presence of esophageal varices (References: Primary Biliary Cirrhosis. Hepatology.
             2009, 50 (1) :291-308.) bedridden patients

        Exclusion Criteria:

          -  Cirrhotic patients with renal failure

          -  Transjugular Intrahepatic Portosystemic Shunt (TIPS)

          -  Cerebral Vascular Event (EVC)

          -  Hepatocellular Carcinoma (HCC)

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Torre Delgadillo, M.D. M.S.ci</last_name>
    <role>Principal Investigator</role>
    <affiliation>INCMNSZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldo Torre Delgadillo, M.D. M.Sci</last_name>
    <phone>54870900</phone>
    <phone_ext>2709</phone_ext>
    <email>detoal@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <state>D.F</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo</last_name>
    </contact>
    <investigator>
      <last_name>Aldo Torre Delgadillo, M.D. M.S.ci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <state>D.F</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Torre Delgadillo, M.D M.S.ci</last_name>
      <phone>54870900</phone>
      <phone_ext>2709</phone_ext>
      <email>detoal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Aldo Torre Delgadillo, M.D M.S.ci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>Investigador Oficial</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis,Infection, Impedance, Body Composition</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
